Root-hair endophyte stacking in finger millet creates a physicochemical barrier to trap the fungal pathogen Fusarium graminearum

The ancient African crop, finger millet, has broad resistance to pathogens including the toxigenic fungus Fusarium graminearum. Here, we report the discovery of a novel plant defence mechanism resulting from an unusual symbiosis between finger millet and a root-inhabiting bacterial endophyte, M6 (Enterobacter sp.). Seed-coated M6 swarms towards root-invading Fusarium and is associated with the growth of root hairs, which then bend parallel to the root axis, subsequently forming biofilm-mediated microcolonies, resulting in a remarkable, multilayer root-hair endophyte stack (RHESt). The RHESt results in a physical barrier that prevents entry and/or traps F. graminearum, which is then killed. M6 thus creates its own specialized killing microhabitat. Tn5-mutagenesis shows that M6 killing requires c-di-GMP-dependent signalling, diverse fungicides and resistance to a Fusarium-derived antibiotic. Further molecular evidence suggests long-term host-endophyte-pathogen co-evolution. The end result of this remarkable symbiosis is reduced deoxynivalenol mycotoxin, potentially benefiting millions of subsistence farmers and livestock. Further results suggest that the anti-Fusarium activity of M6 may be transferable to maize and wheat. RHESt demonstrates the value of exploring ancient, orphan crop microbiomes

Volatile organic compounds emitted by Trichoderma species mediate plant growth

Background: Many Trichoderma species are applied as biofungicides and biofertilizers to agricultural soils to enhance crop growth. These filamentous fungi have the ability to reduce plant diseases and promote plant growth and productivity through overlapping modes of action including induced systemic resistance, antibiosis, enhanced nutrient efficiency, and myco-parasitism. Trichoderma species are prolific producers of many small metabolites with antifungal, antibacterial, and anticancer properties. Volatile metabolites of Trichoderma also have the ability to induce resistance to plant pathogens leading to improved plant health. In this study, Arabidopsis plants were exposed to mixtures of volatile organic compounds ( VOCs) emitted by growing cultures of Trichoderma from 20 strains, representing 11 different Trichoderma species. Results: We identified nine Trichoderma strains that produced plant growth promoting VOCs. Exposure to mixtures of VOCs emitted by these strains increased plant biomass (37.1–41.6 %) and chlorophyll content (82.5–89.3 %). Trichoderma volatile-mediated changes in plant growth were strain-and species-specific. VOCs emitted by T. pseudokoningii (CBS 130756) were associated with the greatest Arabidopsis growth promotion. One strain, T. atroviride (CBS 01-209), in our screen decreased growth (50.5 %) and chlorophyll production (13.1 %). Similarly, tomatoes exposed to VOCs from T. viride (BBA 70239) showed a significant increase in plant biomass (\u3e99 %), larger plant size, and significant development of lateral roots. We also observed that the tomato plant growths were dependent on the duration of the volatile exposure. A GC–MS analysis of VOCs from Trichoderma strains identified more than 141 unique compounds including several unknown sesquiterpenes, diterpenes, and tetraterpenes. Conclusions: Plants grown in the presence of fungal VOCs emitted by different species and strains of Trichoderma exhibited a range of effects. This study demonstrates that the blend of volatiles produced by actively growing fungi and volatile exposure time in plant development both influence the outcome of volatile-mediated interactions. Only some of our growth promoting strains produced microbial VOCs known to enhance plant growth. Compounds such as 6-pentyl-2H-pyran-2-one were not common to all promoting strains. We found that biostimulatory strains tended to have a larger number of complex terpenes which may explain the variation in growth induced by different Trichoderma strains

Defining the optimal sequence for the systemic treatment of metastatic breast cancer.

Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered in the previous stages, such as acquired resistance, type of progression, time to relapse, tumor aggressiveness, age, comorbidities, pre- and post-menopausal status, and patient preferences. Moreover, tumor genomic signatures can identify different subtypes, which can be used to create patient profiles and design specific therapies. However, there is no consensus regarding the best treatment sequence for each subgroup of patients. During the SABCC Congress of 2014, specialized breast cancer oncologists from referral hospitals in Europe met to define patient profiles and to determine specific treatment sequences for each one. Conclusions were then debated in a final meeting in which a relative degree of consensus for each treatment sequence was established. Four patient profiles were defined according to established breast cancer phenotypes: pre-menopausal patients with luminal subtype, post-menopausal patients with luminal subtype, patients with triple-negative subtype, and patients with HER2-positive subtype. A treatment sequence was then defined, consisting of hormonal therapy with tamoxifen, aromatase inhibitors, fulvestrant, and mTOR inhibitors for pre- and post-menopausal patien ts; a chemotherapy sequence for the first, second, and further lines for luminal and triple-negative patients; and an optimal sequence for treatment with new antiHER2 therapies. Finally, a document detailing all treatment sequences, that had the agreement of all the oncologists, was drawn up as a guideline and advocacy tool for professionals treating patients with this disease